A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Helus Pharma’s Phase 3 trial is on track, but real results are years away.

What the company is saying

Helus Pharma (NASDAQ:HELP) is positioning itself as a late-stage innovator in psychiatric drug development, emphasizing steady clinical progress and regulatory recognition. The company’s core narrative is that HLP003, its lead candidate for major depressive disorder (MDD), is advancing efficiently through a robust Phase 3 program, with the APPROACH trial surpassing 86% enrollment and a topline data readout expected in Q4 2026. Management highlights the prior receipt of FDA Breakthrough Therapy Designation for HLP003, using this as a signal of regulatory validation, while also referencing strong Phase 2 efficacy data—specifically, a ~23-point MADRS reduction and high response/remission rates at 12 months. The announcement is careful to stress that these results are company-reported and have not been evaluated by the FDA, and that Breakthrough Therapy Designation does not guarantee approval. The communication style is measured and factual, with a neutral tone and explicit caveats about the investigational status of both HLP003 and HLP004. Eric So, Interim Chief Executive Officer, is the only notable individual identified, and his involvement signals continuity in leadership but does not introduce external institutional credibility or new strategic direction. The company’s messaging fits a classic biotech playbook: focus on clinical milestones, regulatory progress, and future potential, while downplaying the absence of commercial revenue or financial data. Compared to typical biotech communications, Helus is more restrained, explicitly acknowledging the limitations of its current data and the long road to commercialization.

What the data suggests

The disclosed numbers are limited to clinical trial progress and efficacy metrics from earlier-stage studies. The APPROACH Phase 3 trial has surpassed 86% enrollment, which is a concrete operational milestone as of June 24, 2026, but does not speak to efficacy or commercial prospects. The company’s Phase 2 data show a ~23-point reduction in MADRS scores at 12 months after two 16 mg doses, with response rates improving from 75% at week 18 to 100% at 12 months, and remission rates at 71% at 12 months. These figures, while promising, are self-reported and not independently validated or reviewed by the FDA. There is no financial data—no revenue, expenses, cash position, or burn rate—so the company’s financial trajectory cannot be assessed. No information is provided about whether prior clinical or operational targets have been met or missed, and there is no historical baseline for comparison. The quality of clinical disclosures is high in terms of specificity and time-stamping, but the absence of financial and pipeline-wide metrics is a significant gap. An independent analyst would conclude that the company is executing on its stated clinical plan, but that the evidence is limited to operational progress and unconfirmed efficacy signals, with no visibility into financial health or sustainability.

Analysis

The announcement is measured in tone, focusing on the factual milestone of surpassing 86% enrollment in a Phase 3 trial and providing specific, historical Phase 2 efficacy data. While there are forward-looking statements about a topline data readout in Q4 2026 and aspirations for commercialization, these are clearly identified as projections and are not exaggerated relative to the evidence. The company explicitly notes that the FDA has not evaluated the efficacy claims and that Breakthrough Therapy Designation does not guarantee approval, which tempers any promotional language. There is no mention of new capital outlay or immediate commercial impact, and the only realized progress is the enrollment milestone. The gap between narrative and evidence is minimal, with most claims either realized or appropriately caveated.

Risk flags

• ●The majority of the company’s claims are forward-looking, with the key value driver—Phase 3 efficacy and safety data—not available until Q4 2026. This exposes investors to significant timeline and execution risk, as the outcome of the trial is both binary and distant.
• ●There is a complete absence of financial disclosure in the announcement. Investors have no visibility into Helus Pharma’s cash position, burn rate, or funding runway, making it impossible to assess whether the company can sustain operations through the Phase 3 readout.
• ●All efficacy data cited is from company-reported Phase 2 results, which have not been evaluated or confirmed by the FDA or any independent body. This raises the risk that the results may not be reproducible in the larger, more rigorous Phase 3 setting.
• ●The company explicitly notes that Breakthrough Therapy Designation does not guarantee approval, and that neither HLP003 nor HLP004 has been approved by any regulatory authority. This is a critical caveat, as many investors overestimate the predictive value of such designations.
• ●Operational risk remains high: while 86% enrollment is a positive milestone, the final 14% can be the most challenging, and there is no information on dropout rates, protocol amendments, or interim safety signals.
• ●There is no mention of partnerships, licensing deals, or external validation from major pharmaceutical companies or institutional investors. This lack of third-party endorsement increases the risk that the company is operating in isolation, with limited external scrutiny.
• ●The announcement references a broader Phase 3 program (PARADIGM) and a second asset (HLP004), but provides no data or status updates on these, raising questions about pipeline depth and resource allocation.
• ●Eric So is identified as Interim CEO, which may signal leadership instability or a pending transition. While continuity is maintained, the lack of a permanent CEO could impact strategic execution and investor confidence.

Bottom line

For investors, this announcement is a straightforward clinical progress update: Helus Pharma has reached a late-stage enrollment milestone in its lead Phase 3 trial for HLP003, but all meaningful value realization is at least two years away. The company’s narrative is credible in terms of operational execution, but the absence of financial data and the reliance on unvalidated Phase 2 efficacy results are significant limitations. No notable institutional figures or external partners are involved, so there is no added credibility or de-risking from third-party validation. To materially change this assessment, Helus would need to disclose its cash runway, funding plans, or secure a partnership/licensing deal with a larger pharmaceutical company. Investors should watch for updates on final enrollment, interim safety data, and any signals of financial distress or dilution risk in the next reporting period. This information is best treated as a monitoring signal, not a call to action—there is no near-term catalyst, and the risk/reward profile is highly asymmetric and long-dated. The single most important takeaway is that Helus Pharma’s story hinges entirely on a Phase 3 readout in late 2026; until then, the investment case is speculative and exposed to both clinical and financial uncertainty.

Announcement summary

(NASDAQ: HELP) Helus Pharma™ reported that its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026. The company disclosed that HLP003 previously received Breakthrough Therapy Designation from the U.S. FDA. Company-reported Phase 2 results showed a ~23-point MADRS reduction from baseline at 12 months after two 16 mg doses three weeks apart, with response/remission rates of 75% at week 18 improving to 100% response and 71% remission at 12 months. The broader Phase 3 program, called PARADIGM, includes the APPROACH, EMBRACE, and EXTEND studies. Helus Pharma™ operates across Canada, the United States, the United Kingdom, and Ireland. The company projects a topline data readout in the fourth quarter of 2026 and aims to advance HLP003 toward potential commercialization. The FDA has not evaluated the Phase 2 results or confirmed any efficacy claims for HLP003.

Disagree with this article?